ECM
PTGX icon

Evergreen Capital Management’s Protagonist Therapeutics PTGX Stock Holding History

Evergreen Capital Management’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$347K Buy
2,830
+10
+0.4% +$1.04K 0.01% 1126
2026
Q1 		$297K Buy
2,820
+8
+0.3% +$708 0.01% 1129
2025
Q4 		$246K Buy
+2,812
New +$230K 0.01% 1173

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Evergreen Capital Management's PTGX Position: Q2 2026 in Review

Evergreen Capital Management increased its Protagonist Therapeutics (PTGX) stake by 0.35% in Q2 2026, buying an estimated $1.04K and bringing the position to 2,830 shares worth $347K. The position accounts for 0.01% of the portfolio, ranked #1126.

Evergreen Capital Management first reported a position in PTGX in Q4 2025 and has held it in 3 quarters since. 344 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

  • Evergreen Capital Management held 2,830 shares of Protagonist Therapeutics worth $347K as of Q2 2026.
  • Evergreen Capital Management bought 10 Protagonist Therapeutics shares in Q2 2026, an estimated $1.04K.
  • Protagonist Therapeutics made up 0.01% of Evergreen Capital Management's portfolio in Q2 2026, its #1126 holding.
  • Evergreen Capital Management first reported a position in Protagonist Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 344 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Evergreen Capital Management's 13F filing for Q2 2026, filed 23 Jul 2026.